At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 338 enrolled
Drug / intervention
Guselkumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area (BSA) Moderate Plaque Psoriasis With Special Site Involvement
In Brief
A Phase 3 clinical trial evaluating Guselkumab and Placebo for Moderate Plaque Psoriasis. Completed, enrolled 338 participants across 64 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate plaque psoriasis and special site involvement.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate Plaque Psoriasis
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
Enrollment StartAug 2023
First PostedSep 2023
Primary CompletionApr 2025
TodayJul 2026
First PostedSep 15, 2023
Enrollment StartAug 24, 2023
Primary CompletionApr 14, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 2.8 years ago
Interventions
Guselkumabdrug
Guselkumab will be administered as subcutaneous injection.
Placebodrug
Placebo will be administered as subcutaneous injection.